Comparative Pharmacology
Head-to-head clinical analysis: GLATOPA versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLATOPA versus TERIFLUNOMIDE.
GLATOPA vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glatiramer acetate (GLATOPA) is a mixture of synthetic polypeptides that alters immune processes by inducing and expanding T-helper 2 (Th2) regulatory cells, which suppress pro-inflammatory T-helper 1 (Th1) cells. It also competes with myelin basic protein for binding to major histocompatibility complex (MHC) molecules, thereby modulating antigen presentation and reducing autoimmune attack on myelin.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
20 mg subcutaneously once daily.
7 mg orally once daily with or without food.
None Documented
None Documented
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
The terminal elimination half-life of glatiramer is approximately 1.5–2 hours after subcutaneous administration. This short half-life is due to rapid proteolytic degradation; however, the clinical effect persists for days due to immunological mechanisms.
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Glatiramer acetate is extensively metabolized locally at the injection site and systemically by proteolysis. The metabolites are eliminated primarily via renal excretion (approximately 70%) and biliary/fecal excretion (approximately 30%). Less than 1% is excreted unchanged.
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category C
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."